tiprankstipranks
Arvinas downgraded to Neutral at Guggenheim on rising ARV-471 risks
The Fly

Arvinas downgraded to Neutral at Guggenheim on rising ARV-471 risks

Guggenheim analyst Michael Schmidt downgraded Arvinas (ARVN) to Neutral from Buy and removed his prior price target of $66 on the shares following company disclosures this week that he sees raising the development and timeline risks for lead program ARV-471. Arvinas disclosed that its combination studies of ARV-471 with Pfizer’s (PFE) palbociclib require additional dosing work and regulatory feedback before initiating Phase III development in first-line mBC and that initiation of the planned first-line mBC trial has been pushed back by about 6-12 months, noted Schmidt, who sees this extending the development gap versus potential competitor SERD programs from Roche (RHHBY), Eli Lilly (LLY) and AstraZeneca (AZN).

Published first on TheFly

See Insiders’ Hot Stocks on TipRanks >>

Read More on ARVN:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles